DiabetesSource

Secretagogues increase insulin release from the pancreas by increasing the signaling to the pancreas. This increase of insulin helps decrease glucose levels; however, the extra workload on the pancreas can result in faster beta cell burnout which will eventually result in reduced insulin output. This class of secretagogues is short-acting and helps restore first-phase insulin release while preserving beta cell function.

Prandin® (repaglinide) Tablets Novo Nordisk Inc. Prandin® may be dosed preprandially 2, 3 or 4 times a day in response to changes in the patient's meal pattern. The maximum recommended daily ...More
Starlix® (nateglinide) Tablets Novartis Pharmaceuticals Corporation Starlix® (nateglinide) Tablets are oral anti-diabetic agents in meglitinide class used in the management of Type 2 diabetes mellitus. Recommended starting ...More